Cleveland Clinic and partners address treatment, funding, research challenges
Cleveland Clinic, University Hospitals Case Medical Center and Case Western Reserve University are partners in the Case Comprehensive Cancer Center (CCCC), which integrates cancer treatment, research, clinical trials, prevention, screening and education activities in Northern Ohio. This collaborative pools the expertise and resources of its three member institutions and leverages those to acquire research funding and provide advanced cancer care. It is one of 41 National Cancer Institute-designated comprehensive cancer centers nationwide, and one of only a handful of “matrix” centers composed of multiple, independent partners.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
“We honestly believe that the sum of the parts greatly exceeds one plus one plus one,” says Brian Bolwell, MD, Chairman of Cleveland Clinic’s Taussig Cancer Institute and CCCC Associate Director.
From Science to Cancer Cures Panel Video
In this video, Dr. Bolwell and fellow CCCC leaders participate in a recent panel discussion organized by the City Club of Cleveland: “From Science to Cancer Cures: How the Case Comprehensive Cancer Center Makes the City of Cleveland Better.” Topics include cancer research projects underway at CCCC; the state of cancer research funding; population-based research and disparities in cancer incidence and treatment access in Northern Ohio; genetic/genomic screening and predictors of cancer risk; integrative oncology; the importance of translational research, and potential solutions for the escalating cost of cancer care.
Photo credit: ©The City Club of Cleveland
Timing and type of side effects differ greatly from chemotherapy
Dedicated multidisciplinary teams support 84 ultra-rare cancers
Sessions explore treatment advances and multidisciplinary care
New research from Cleveland Clinic helps explain why these tumors are so refractory to treatment, and suggests new therapeutic avenues
Combination of olaparib and carboplatin results in complete durable response for a patient with BRCA2 and “BRCAness” mutations
Early communication between oncologists and ophthalmologist warranted
Case-based course delves into latest treatment approaches
Long-term relationship building and engagement key to gaining community trust